PLASMA ASYMMETRIC DIMETHYLARGININE LEVEL AND THE ASSOCIATION WITH CARDIOVASCULAR RISK FACTORS IN END STAGE CHRONIC KIDNEY DISEASE

Objectives: we aimed to assess the levels of plasma ADMA in end stage renal disease (ESRD) patients without dialysis and its association with cardiovascular risk factors. Materials and Methods: This is a controlled cross-sectional study. Plasma ADMA level and other variables were measured in 30 patients of ESRD without dialysis and in 30 control healthy persons. Plasma ADMA levels were determined by enzyme linked immunosorbent assay (ELISA) using kits provided by immunodiagnostic AG, Germany. Data was analyzed by SPSS 19.0. Results: Mean level of ADMA in ESRD patients was 0.88 ± 0.27 µmol/L. Mean level of ADMA in healthy people was 0.49 ± 0.13 µmol/L, with significiant difference (p<0.01). There was not significiant difference of mean level of ADMA between male and female. Plasma ADMA levels were not correlated with age, serum CRP and cholesterol levels. There were correlation between ADMA level and BMI (r=-0.31, p<0.05), and Hb level (r=-0.58, p<0.01), and Hct (r=-0.60, p<0.01). It existed correlation between ADMA level and estimated glomerular filtration rate (GFR) (r=-0.63, p<0.01). Conclusion: In ESRD, mean level of ADMA is 0.88 ± 0.27 µmol/L. There is a significiant elevation of ADMA level in ESRD compared to healthy people. A negative correlation exists between ADMA level with BMI, Hb level, Hct and eGFR. Key words: Asymmetric dimethylarginine, end stage chronic kidney disease, cardiovascular risk factor, correlation.